You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR SCANLUX-300

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for SCANLUX-300

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04375787 ↗	Atorvastatin Effect on Contrast Induced Nephropathy in Diabetic Patients Undergoing Elective Coronary Intervention	Completed	Mohamed Abdelfatah	Phase 4	2020-03-15	Investigate of the potential benefit of acute pretreatment with high dose atorvastatin (80 mg) in reduction of the incidence of CIN in diabetic patients indicated for elective coronary intervention.
NCT04504331 ↗	Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer	Recruiting	Breast Cancer Research Foundation	Phase 1	2020-10-13	The purpose of the study is identify the dose(s) of infigratinib to use in combination with tamoxifen to treat patients with a particular type of advanced breast cancer (hormone receptor-positive, HER2-negative, FGFR-altered breast cancer)
NCT04504331 ↗	Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer	Recruiting	National Cancer Institute (NCI)	Phase 1	2020-10-13	The purpose of the study is identify the dose(s) of infigratinib to use in combination with tamoxifen to treat patients with a particular type of advanced breast cancer (hormone receptor-positive, HER2-negative, FGFR-altered breast cancer)
NCT04504331 ↗	Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer	Recruiting	QED Therapeutics, Inc.	Phase 1	2020-10-13	The purpose of the study is identify the dose(s) of infigratinib to use in combination with tamoxifen to treat patients with a particular type of advanced breast cancer (hormone receptor-positive, HER2-negative, FGFR-altered breast cancer)
NCT04504331 ↗	Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer	Recruiting	Stanford University	Phase 1	2020-10-13	The purpose of the study is identify the dose(s) of infigratinib to use in combination with tamoxifen to treat patients with a particular type of advanced breast cancer (hormone receptor-positive, HER2-negative, FGFR-altered breast cancer)
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for SCANLUX-300

Condition Name

Chart
Table

Condition Name for SCANLUX-300
Intervention	Trials
Breast Cancer	1
Coronary Disease	1
ER Positive Breast Cancer	1
ER-Negative Breast Cancer	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for SCANLUX-300
Intervention	Trials
Coronary Disease	1
Breast Neoplasms	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for SCANLUX-300

Trials by Country

Map
Table

Trials by Country for SCANLUX-300
Location	Trials
United States	1
Egypt	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for SCANLUX-300
Location	Trials
California	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for SCANLUX-300

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for SCANLUX-300
Clinical Trial Phase	Trials
Phase 4	1
Phase 1	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for SCANLUX-300
Clinical Trial Phase	Trials
Completed	1
Recruiting	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for SCANLUX-300

Sponsor Name

Chart
Table

Sponsor Name for SCANLUX-300
Sponsor	Trials
Mohamed Abdelfatah	1
Breast Cancer Research Foundation	1
National Cancer Institute (NCI)	1
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for SCANLUX-300
Sponsor	Trials
Other	3
NIH	1
Industry	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.